Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 2Recurrence 1Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Rituximab 344Cyclophosphamide 317fludarabine phosphate 142Etoposide 139Peripheral Blood Stem Cell Transplantation 124fludarabine 112Filgrastim 112Mycophenolic Acid 98Melphalan 98Whole-Body Irradiation 90Vincristine 90Busulfan 87Cytarabine 85Doxorubicin 79Cyclosporine 76Tacrolimus 75Radiotherapy 75Prednisone 73Bendamustine Hydrochloride 72Granulocyte Colony-Stimulating Factor 66Methotrexate 65Antilymphocyte Serum 56Carmustine 54Dexamethasone 50Gemcitabine 48Lenalidomide 46Bortezomib 43venetoclax 41ibritumomab tiuxetan 37obinutuzumab 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Non-Hodgkin × tapotoclax × Clear all
NCT03797261 2021-12-07

A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies

AbbVie

Phase 1 Terminated
9 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Neoplasms, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡